Grant: Project Grant
University of British Columbia
$1,147,500.00
Identifying mediators of drug tolerance and persister cell survival in response to targeted therapies in lung adenocarcinoma
FY 2025-26
Summary
Lung cancer is one of the deadliest cancers worldwide. Some forms of lung cancer are driven by genetic changes in genes called EGFR and KRAS. While there are drugs designed to target these mutations, they often stop working over time because cancer cells find ways to survive. This project aims to uncover how cancer cells become resistant to treatment and find new ways to prevent this from happening.
First, we will use a special genetic tool called the "Sleeping Beauty" system to discover the hidden changes in cancer cells that help them survive drug treatments. In parallel, we will confirm which of these changes are truly important by using advanced gene-editing techniques (CRISPR) in lab-grown cancer cells and mouse models. Finally, we will test new drug combinations to see if we can block these survival tricks and make current treatments work better and last longer.
Our goal is to help develop smarter, more effective treatments for lung cancer patients, giving them better chances for longer, healthier lives.
Department
Program
Project Grant
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
565719
Name
Lockwood William W
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics 2
Projecttitle
Identifying mediators of drug tolerance and persister cell survival in response to targeted therapies in lung adenocarcinoma
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$1,147,500
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Drug Resistance; Drug Tolerance; Egfr; Functional Genomics; Kras; Lung Cancer; Mouse Models; Targeted Therapy
Abstract
Lung cancer is one of the deadliest cancers worldwide. Some forms of lung cancer are driven by genetic changes in genes called EGFR and KRAS. While there are drugs designed to target these mutations, they often stop working over time because cancer cells find ways to survive. This project aims to uncover how cancer cells become resistant to treatment and find new ways to prevent this from happening.
First, we will use a special genetic tool called the "Sleeping Beauty" system to discover the hidden changes in cancer cells that help them survive drug treatments. In parallel, we will confirm which of these changes are truly important by using advanced gene-editing techniques (CRISPR) in lab-grown cancer cells and mouse models. Finally, we will test new drug combinations to see if we can block these survival tricks and make current treatments work better and last longer.
Our goal is to help develop smarter, more effective treatments for lung cancer patients, giving them better chances for longer, healthier lives.
Competitiondate
202603
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Lockwood, William W
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $1,147,500~ $0~
